logo-loader
viewTaylor Wimpey

Persimmon and Taylor Wimpey flourish after American bank issues 'double-upgrades'

Its stance on the sector as a whole as also become 'less negative'

building site
Market conditions appear a little brighter than the share prices of most builders would suggest

What does Bank of America Merrill Lynch know about Brexit that the rest of the market has overlooked?

For it has made a raft of upgrades across the UK house-building sector on the “assumption that a hard, or no deal Brexit is avoided.

That’s a big assumption given the parliamentary deadlock over the issue.

Persimmon (LON:PSN) and Taylor Wimpey (LON:TW.) – up 3.3% and 3.9% respectively – were the beneficiaries of double upgrades (from ‘underperform’ to ‘buy’) and are now BofA’s two top picks.

Cash generation is key 

It likes the cash generation capabilities of both companies especially when converted (and have the ability to continue to convert) into ordinary and special dividend payments.

Barratt (LON:BDEV), Bellway (LON:BLWY), Bovis (LON:BVS) and Berkeley (LON:BKY) were all upped to ‘neutral’ from ‘underperform’. Redrow (LON:RDW) was kept at ‘underperform’.

Taylor Wimpey’s update earlier this week suggested the sector still had some steam left.

It completed 14,947 new homes, for a rise of 3%, while its order book grew to £1.78bn.

Taylor Wimpey confounds bears

“Despite wider macroeconomic uncertainty, the housing market remained stable during 2018 and we had a good trading performance,” said Pete Redfern, the chief executive.

The company reiterated its aim to return £600mln to investors, which equates to just over 18p a share.

Returning to the BofA note, the American bank’s analysts have shifted their stance on the sector as a whole to neutral from negative.

In order to become more positive, it said it would need to be convinced interest rates were not going up, GDP will accelerate (not decelerate), there’s no shortage of skilled labour and that there really is a structural under-supply of housing in the UK.

Quick facts: Taylor Wimpey

Price: 173.95 GBX

LSE:TW.
Market: LSE
Market Cap: £5.71 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn reveals its drug inhibits colon carcinoma metastases...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive its flagship drug leronlimab inhibited a human colon carcinoma cell line metastases to liver and lung in a well-accepted mouse model. Pourhassan says the company plans to file an IND for expanded access for a Phase 2 basket...

10 hours, 40 minutes ago

RNS

Director/PDMR Shareholding

1 hour, 2 minutes ago

Director/PDMR Shareholding

5 days, 19 hours ago

Trading Statement

1 week ago

Director/PDMR Shareholding

1 week, 2 days ago

Total Voting Rights

2 weeks, 5 days ago

Change of Adviser

on 10/18/2019

2 min read